In our analyses of risk rate not adjusted for time, we found a significantly increased risk of metastatic disease in patients with pathogenic germline variants in SDHA, SDHB, SDHC, TMEM127, MAX, and FH compared to those with no identified pathogenic variant. Here, SDHC is linked to metastatic neoplasm.